Biotechnology was full of success stories in 2013. And some of
those stories just got more exciting in February as the Nasdaq
Biotech Index (IBB) rallied 13% off the lows. My FTM Portfolio also
surged higher on the back of names like
(ALXN) was one of the heavy lifters of that IBB performance since
it comprises nearly 5% of that index. ALXN shares rallied 17% this
month to hit an all-time closing high of $181.52 after a strong
quarterly report in late January that first vaulted the stock over
20% in one day from the low $130s to over $160.
What was all the excitement about that had this biotech superstar
making a $50 (nearly 40%) move in under 3 weeks? Sales and taxes,
Alexion's revenues jumped 38% to approximately $442 million in the
final quarter of 2013 -- beating the consensus by over $10 million
-- driven by strong sales of their key drug Soliris, which is the
only treatment available for paroxysmal nocturnal hemoglobinuria
PNH is a rare genetic blood disorder characterized by the onset of
severe hemolytic anemia, chronic fatigue and intermittent episodes
of dark colored urine, known as hemoglobinuria. Because of the
life-saving benefits for these patients that only come from
Soliris, major insurance companies support one of the highest price
tags of any drug treatment at roughly $440,000.
This may seem unfair to some minds, but Alexion was founded in 1992
and it's been a long and bumpy road to profitability. If biotech
companies don't have visibility on potential financial outcomes,
they cannot invest the billions in laboratory and clinical R&D
necessary to discover specialized drug therapies that are both
effective and safe in treating rare diseases that may only afflict
a few thousand people.
In 2011, the FDA cleared Soliris for treating children and adults
suffering from atypical hemolytic uremic syndrome (aHUS), an
ultra-rare genetic disorder. In Nov 2011, a similar approval for
the drug was granted in the EU. Japanese approval for the aHUS
indication came in Sep 2013.
While Alexion is testing Soliris and a number of other compounds in
a variety of different disease indications, the drug recorded sales
of $1.55 billion in 2013, up 37%.
Irish Tax Haven
Besides raising guidance on sales of Soliris to $2 billion for
2014, the company detailed plans for exceptional corporate tax
savings as they develop operations in Ireland. This reworking of
Alexion's tax structure was largely unexpected by analysts who were
modeling a tax rate for 2014 coming into the quarter of 23%
compared with the new 11% revealed last month.
The company informed investors in their last conference call that
effective from 2014, its Irish units are holding certain
intellectual property rights to Soliris and other compounds.
Obviously the company stands to benefit greatly from lower tax
rates thus aiding its long-term growth prospects.
But the move also makes sense for a global pharma company providing
disease treatment around the world to centralize operations in
tax-friendly region with a strong pool of biopharma workers.
Alexion also stated that it intends to utilize its net operating
loss (NOL) balance (approximately $9 million at the end of 2013) as
well as tax credits ($190 million at the end of 2013) to offset its
These measures are reflected in the company s adjusted tax rate
projections of 11%-12% for 2014, 13%-14% in 2015, and 16%-18% in
2018. The move to invest heavily in Ireland is indicative of
management's efforts to increase shareholder value.
Following these announcements in late January, Wall Street analysts
began revising their models for Connecticut-based ALXN.
Stifel Nicolaus raised their earnings estimates and price target to
$207 from $138 citing that the FY14 bottom-line guidance provided
the first glimpse of longer-term earnings leverage associated with
the completion of the offshore operational realignment that would
"optimize" the company's longer-term tax rate structure, generating
more than $20 per share in incremental upside.
Both Canaccord Genuity and Brean Capital analysts were out
immediately after the company report on January 30 and raised their
outlooks and price targets to $200. On February 7, the stock began
making the move up from $155 and on Feb 10, Deutsche Bank sealed
the deal with their PT bump from $125 to $205.
With consensus projections for EPS of $4.76 in 2015, here's what
the growth trajectory looks like for Alexion based solely on
ALXN Pipeline and Valuation
But those estimates could accelerate even higher in the coming
years as the company develops its drug pipeline. Stifel analysts
also noted that they expect an improving catalyst calendar and an
expanding/diversified pipeline to further support additional
multiple expansion for ALXN shares.
Alexion currently has several candidates in clinical development
focusing on different areas. Alexion expects to launch seven
products in the 2014-2018 time frame. And the company inked a deal
with the privately held Moderna Therapeutics in January for the
discovery and development of messenger ribo nucleic acid (mRNA)
therapeutics to treat patients suffering from rare diseases.
Most developmental biopharma companies face regulatory risk as they
run the FDA gauntlet. But William Blair analysts explain the extra
challenges for Alexion...
Because the company targets "ultraorphan" markets with its drug
therapies, where the diseases are often poorly characterized and
few alternative therapeutic options exist, they face FDA approval
pathways that are not always well-defined, and any regulatory
setbacks with investigational compounds in Alexion's pipeline could
pressure the shares.
Alexion's trailing 12-month price-to-sales multiple is 20X,
compared to its peer group multiple of 9.4. With a $35.3 billion
market cap, the stock is trading over 17.5 X 2014 sales estimates,
above its peer group multiple of 9X. On a P/E basis, ALXN is
trading at just over 50X this year's earnings estimates of $3.50.
Apparently the analysts are quite comfortable with this valuation
for a biopharma company with a blockbuster drug, an expanding
pipeline, and the loopholes of the Irish.
Disclosure: I own PCYC, MDVN, and ALNY for the Zacks FTM Portfolio.
Kevin Cook is a Senior Stock Strategist for Zacks where he runs
Follow The Money
ALNYLAM PHARMA (ALNY): Free Stock Analysis
ALEXION PHARMA (ALXN): Free Stock Analysis
ISHARES NDQ BIO (IBB): ETF Research Reports
MEDIVATION INC (MDVN): Free Stock Analysis
PHARMACYCLICS (PCYC): Free Stock Analysis
To read this article on Zacks.com click here.